Insider Selling: Artivion (NYSE:AORT) CEO Sells $787,961.58 in Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 20,962 shares of Artivion stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $787,961.58. Following the transaction, the chief executive officer owned 780,031 shares in the company, valued at $29,321,365.29. This trade represents a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Artivion Stock Performance

Shares of AORT opened at $38.52 on Friday. The business has a 50-day simple moving average of $41.93 and a two-hundred day simple moving average of $43.02. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.25. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 192.58 and a beta of 1.59.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

A number of hedge funds have recently made changes to their positions in AORT. Squarepoint Ops LLC bought a new position in shares of Artivion during the 2nd quarter valued at approximately $664,000. Kennedy Capital Management LLC raised its stake in Artivion by 20.8% during the second quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock valued at $11,437,000 after purchasing an additional 63,205 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in Artivion during the second quarter valued at $669,000. Sio Capital Management LLC grew its stake in shares of Artivion by 31.0% in the 2nd quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock worth $4,937,000 after buying an additional 37,558 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of Artivion during the 2nd quarter valued at about $3,750,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Canaccord Genuity Group dropped their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Citizens Jmp increased their target price on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Finally, Oppenheimer reissued an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.